HFpEF is a form of heart failure in which the heart's pumping strength remains normal, but the heart muscle becomes stiff and cannot relax properly between beats.

Because the heart cannot fill efficiently, pressure builds inside the heart and lungs, leading to symptoms such as:

• Shortness of breath

• Fatigue

• Exercise intolerance

• Swelling in the legs or ankles

• Difficulty lying flat

• Reduced quality of life

HFpEF now accounts for approximately half of all heart failure cases and is becoming increasingly common as the population ages.

Atrial fibrillation (AF) is the most common sustained heart rhythm disorder.

Instead of beating in a coordinated fashion, the upper chambers of the heart (the atria) activate rapidly and irregularly. This causes the atria to lose their normal pumping function and can produce an irregular heartbeat, palpitations, fatigue, dizziness, and shortness of breath.

AF also increases the risk of stroke and hospitalization and can significantly affect quality of life.

The left atrium plays an important role in helping fill the left ventricle with blood.

In HFpEF, elevated filling pressures place extra stress on the left atrium, causing it to enlarge, stiffen, and develop fibrosis (scar tissue). These structural changes increase the likelihood of atrial fibrillation.

Once AF develops, the atria lose their coordinated contraction, further reducing the heart's ability to fill efficiently. This can worsen heart failure symptoms and create a cycle in which each disease accelerates the progression of the other.

The atria do more than simply conduct electrical signals. They serve as:

• Reservoirs, storing blood returning from the lungs

• Conduits, allowing blood to flow into the ventricles

• Booster pumps, actively contracting to improve ventricular filling

In patients with HFpEF, these functions become increasingly important because the stiff ventricle depends more heavily on effective atrial filling.

Loss of atrial function may contribute to worsening symptoms, reduced exercise capacity, and recurrent hospitalizations.

Current management focuses on controlling symptoms, reducing hospitalization, and improving quality of life.

Treatment may include:

• Lifestyle modification

• Blood pressure management

• Weight management

• Diabetes treatment

• Heart failure medications

• Blood thinners when appropriate

• Rate or rhythm control strategies for atrial fibrillation

• Catheter ablation in selected patients

• Ongoing monitoring and management of contributing conditions

Treatment plans should always be individualized and developed with a healthcare professional.

Researchers around the world are working to better understand the relationship between HFpEF and atrial fibrillation and to develop therapies that improve symptoms, reduce hospitalizations, and preserve heart function.

Emerging approaches include new medications, advanced imaging techniques, implantable monitoring systems, artificial intelligence, and novel device-based therapies designed to better understand, prevent, or treat atrial fibrillation and heart failure. Several companies and academic institutions are also investigating technologies that aim to restore and preserve normal atrial function without destroying atrial tissue.

The HFpEF Navigator is dedicated to following these developments and providing balanced educational information about current treatments, clinical research, and emerging innovations that may shape the future of HFpEF and atrial fibrillation care.

Knowledge empowers patients. Understanding inspires better conversations. Innovation creates hope for the future.